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ABSTRACT
Tissue factor (TF)-producing cells were identified in normal human vessels and atherosclerotic plaques by
in situ hybridization and immunohistochemistry using a specific riboprobe for TF mRNA and a polyclonal antibody
directed against human TF protein. TF mRNA and protein
were absent from endothelial cells lining normal internal
mammary artery and saphenous vein samples. In normal
vessels TF was found to be synthesized in scattered cells present
in the tunica media as well as fibroblast-like adventitial cells
surrounding vessels. Atherosclerotic plaques contained many
cells synthesizing TF mRNA and protein. Macrophages present
as foam cells and monocytes adjacent to the cholesterol clefts
contained TF mRNA and protein, as did mesenchymalappearing intimal cells. Significant TF protein staining was
found deposited in the extracellular matrix surrounding
mRNA-positive cells adjacent to the cholesterol clefts and
within the necrotic cores. These results suggest that deposition
of TF protein in the matrix of the necrotic core of the
atherosclerotic plaque may contribute to the hyperthrombotic
state of human atherosclerotic vessels.

localizations using in situ hybridization and immunohistochemistry. We report here the localization of TF-producing
cells in the normal vessel wall and atherosclerotic plaques.

METHODS
Tissue Preparation. Normal human saphenous veins and
internal mammary arteries were obtained during coronary
bypass surgery. Human atherosclerotic plaques were obtained from patients undergoing carotid endarterectomy
surgery.
The tissue samples were removed and immersed in freshly
prepared 4% (wt/vol) paraformaldehyde in 0.1 M sodium
phosphate (pH 7.4). The tissues were fixed at 40C for 3 hr to
overnight and then immersed in 15% (wt/vol) sucrose/isotonic phosphate-buffered saline for 2-4 hr at 40C to act as a
cryoprotectant. The tissues were then embedded in optimal
cutting temperature compound (O.C.T., Miles Scientific)
blocks and stored at -70°C. Finally, the tissues were sectioned at 10 Am thickness by using a cryostat, thaw-mounted
onto polylysine-coated microscope slides, immediately refrozen, and stored at -70°C with desiccant.
In Situ Hybridization. In situ hybridizations were carried
out as described (16, 17). Prior to hybridization the sections
were pretreated sequentially with paraformaldehyde (10 min)
and with proteinase K at 1 ,g/ml (10 min) and prehybridized
for 1-2 hr in 100 ,ul of prehybridization buffer [50% (vol/vol)
formamide/0.3 M NaCI/20 mM Tris-HCl, pH 8.0/5 mM
EDTA/0.02% polyvinylpyrrolidone/0.02% Ficoll/0.02% bovine serum albumin/10% (wt/vol) dextran sulfate/10 mM
dithiothreitol]. The hybridizations were started by adding
600,000 cpm of the 35S-labeled riboprobe in a small amount of
prehybridization buffer. After hybridization the sections
were washed with 2 x SSC (two 10-min washes; lx SSC =
150 mM NaCl/15 mM sodium citrate, pH 7.0), treated with
RNase (20 ,g/ml for 30 min at room temperature), washed in
2x SSC (two 10-min washes), and washed at high stringency
in 0.1 x SSC at 520C for 2 hr. All SSC solutions up to this point
of the procedure contained 10 mM 2-mercaptoethanol and 1
mM EDTA to help prevent nonspecific binding of the probe.
The tissue was then washed in 0.5x SSC without 2-mercaptoethanol (two 10-min washes) and dehydrated by immersion in a graded alcohol series containing 0.3 M NH4Ac. The
sections were dried, coated with NTB2 nuclear emulsion
(Kodak), and exposed in the dark at 40C for 4-8 weeks. After
development, the sections were counterstained with hematoxylin and eosin.
A cDNA probe specific to human TF subcloned in the SP64
plasmid (Promega Biotec), provided by Karen Fisher and
Richard Lawn (Genentech), was labeled by transcription (18)
using 35S-labeled UTP (specific activity, 1200 Ci/mmol; 1 Ci
= 37 GBq; Amersham). This was a 1.3-kilobase probe and
included the entire coding sequence for human TF extending

Tissue factor (TF) is a membrane-bound glycoprotein that
functions in the extrinsic pathway of blood coagulation by
acting as a cofactor for factor VII (1, 2). TF binds to coagulation factor VII, and the resulting factor VIIa-TF complex
acts as a catalyst for the conversion offactors X to Xa and IX
to IXa, leading to the formation of thrombin (3, 4). Thus, TF
facilitates both intrinsic and extrinsic pathways of coagulation
and is a key protein in the activation of the coagulation
cascade.
TF activity has been isolated from a number of different
tissues and has been cloned from adipose (5), fibroblast (6),
and placental (7, 8) cDNA libraries. A 2.3-kilobase band
corresponding to human TF mRNA has been identified by
Northern blots using RNA from adipose tissue, small intestine, placenta, kidney (5), and brain (8). Cultured endothelial
cells produce low levels of TF mRNA (5). TF procoagulant
activity in endothelial cells is enhanced by the addition of
endotoxin (9), thrombin (10), phorbol esters (9, 11), interleukin 1, or tumor necrosis factor (12, 13) to the culture medium.
TF mRNA has also been identified in the monocyte cell line
U937 (8) and TF activity has been identified in normal
monocytes after activation with endotoxin or phorbol esters
(14, 15).
There is no information concerning the cellular distribution
of TF-producing cells within the tissues from which it has
been isolated. It has been postulated that TF is not exposed
to blood elements but must be associated with the vasculature where it could act quickly in response to vascular
damage. With cDNA probes and antibodies specific for the
TF protein, it is now possible to do more precise cellular
The publication costs of this article were defrayed in part by page charge
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Abbreviation: TF, tissue factor.
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from nucleotide 1 in the 5' flanking region to a HindIII site at
nucleotide 1347 in the 3' untranslated region (5). The final
specific activity of this probe was 300 Ci/mmol.
Immunohistochemistry. TF antibody RD010 was prepared
by immunizing rabbits with recombinant human TF protein
(19). The IgG fraction of the serum was purified by affinity
chromatography on a recombinant human TF-Sepharose
column. This antibody was shown to react with a single band
at 42 kDa on a Western blot, neutralize TF activity, and
immunoprecipitate TF protein (20).
Immunohistochemistry was performed according to the
manufacturer's direction using the Vectastain ABC alkaline
phosphatase system (Vector). The final reaction product was
stained with the alkaline phosphatase substrate kit I to give
a final stain that appeared red.
The affinity-purified TF antibody RD010 was used at a
concentration of 4.4 ,ug/ml. An IgG fraction of the preimmune serum was used as a control for the TF immunohistochemistry at the same IgG concentration as RD010. This
was prepared by passing the preimmune serum over a protein
A-Sepharose column. Additional antibodies specific for human macrophages (ref. 21; HAM56, gift of Allen Gown,
University of Washington), smooth muscle cells (ref. 22;
HHF35, gift of Allen Gown), or human endothelial cells (ref.
23; anti-Ulex lectin, Vector) were used on some serial
sections to aid in cell identification.

RESULTS
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TF Localization in Normal Vessels. Normal human saphenous vein and internal mamamary artery samples (nine
sections for each tissue, three sections from each of three
individuals) were examined for the presence of TF. Endothelial cells were negative for TF mRNA and protein in all
vascular tissues examined. Many scattered cells in the tunica
media of the saphenous vein contained TF mRNA as determined by in situ cRNA hybridization (Fig. lA). Immunohistochemical staining of these cells, however, was very weak
but appeared to be cell-associated and correlated well with
the in situ results (Fig. 1B). The strongest labeling was seen
over the adventitia where adventitial fibroblasts showed
intense TF protein staining (Fig. 1B) and mRNA hybridization. The internal mammary artery samples also showed
positive mRNA hybridization and intense protein labeling
over the adventitial fibroblasts. However, fewer medial cells
contained TF mRNA, as indicated by the in situ hybridization, and no protein could be detected in the media by
immunohistochemistry. Additional normal arteries obtained
from hearts discarded from recipients of transplants were
screened for TF mRNA by in situ hybridization (three
sections each from the following tissues: aorta, n = 2; left
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anterior descending coronary artery, n = 1; right coronary
artery, n = 2; left circumflex artery, n = 1). These arterial
samples came from idiopathic dilated cardiomyopathy hearts
removed at the time of cardiac transplantation. These hearts
typically have no significant atherosclerotic disease, and this
was confirmed in our samples. All of these vessels showed
positive adventitial cells but at most a single medial cell
containing TF mRNA.
In general, more cells were found to be positive in the
media of the saphenous vein by in situ hybridization than
could be detected by immunohistochemical staining. Visual
comparison of the hybridization signal over the adventitial
fibroblasts and that of positive cells in the media suggested
that these cell types do not differ greatly in their content of
TF mRNA. However, a similar comparison of the immunohistochemical staining intensity over these cells suggests that
the adventitial fibroblasts contain much more TF protein than
do the medial cells. This could suggest that there is some
alteration in TF translation or secretion in the medial cells
resulting in the reduced protein content. Alternatively, antibody RD010 may react differently with the TF in the medial
or adventitial cells due to some change in the TF protein
itself.
The morphology of TF-positive cells in the media of the
saphenous vein differed from that of typical smooth muscle
cells. The cytoplasm of the TF-positive cells stained poorly
with eosin and did not display a typical fusiform-shaped
cytoplasm but rather appeared more cuboidal in shape, with
small dense nuclei. Cells with this morphology do not stain
with smooth muscle a-actin antibodies (HHF35; data not
shown) and must be considered undefined, since we lack a
positive immunochemical marker for these cells.
TF Localization in Atherosclerotic Plaques. Human atherosclerotic plaques obtained from carotid endarterectomy surgery were examined for TF mRNA and protein using the
above techniques. Extensive mRNA hybridization was seen
in several regions of atherosclerotic plaque. Positive cells
were found scattered throughout the fibrous cap (Fig. 1C),
the base and shoulder region of the plaque, as well as in the
necrotic core adjacent to the cholesterol clefts (Fig. 1F). Six
plaques were screened and cells showing TF mRNA hybridization were seen in all of them. The normal media underlying
the endarterectomy specimens did not contain any TF protein
or mRNA-positive cells.
The necrotic cores of the plaques were characterized by
extensive TF protein localization in the extracellular matrix
particularly surrounding some cholesterol clefts (Fig. 1 E and
G). Additional protein staining was seen in the macrophagerich foam cell regions of many of the atherosclerotic plaques
examined (Fig. 1D). Such foam cell-rich regions often lay
underneath the fibrous cap and adjacent to the necrotic cores.

FIG. 1. Localization of TF in the normal human saphenous vein (A and B) and in human carotid endarterectomy specimens (C-G). (A) In
situ hybridization using a specific 35S-labeled TF cRNA probe indicated that there were scattered TF-producing cells in the tunica media and
adventitia. (B) Cells containing TF protein were detected by immunocytochemistry using antibody RD010 and the Vectastain alkaline
phosphatase method (positive cells stain red). Scattered cells in the tunica media were lightly stained by antibody RD010, whereas strong
immunohistochemical staining was always seen in the adherent adventitial fibroblasts. Endothelial cells lining the lumen of the normal vessel
were always negative for TF protein and mRNA. L, lumen; M, media; A, adventitia. (C) Localization of TF in the human atherosclerotic plaque
by in situ hybridization. Carotid endarterectomy specimens were hybridized to an 35S-labeled TF riboprobe and revealed many cells producing
TF in the fibrous cap ofthe atherosclerotic plaque. (D) Localization of tissue factor protein in macrophage foam cells of the atherosclerotic plaque
by immunohistochemistry with antibody RD010. (E and F) Colocalization of TF protein and mRNA in the same cells of the plaque. (E)
Immunohistochemistry with TF antibody RD010 indicated strong staining of the necrotic core region of the plaque particularly in areas adjacent
to the cholesterol clefts. (F) In situ hybridization of a section immediately adjacent to the one shown in E indicated that cells containing TF
mRNA were found adjacent to the cholesterol clefts, suggesting local synthesis of the TF protein detected in this region. Not all of the protein
detected here was cell associated. Arrows point to two cholesterol clefts followed on the serial sections. (G and H) Identification of cells
producing TF in the necrotic core of the atherosclerotic plaque. Serial sections stained with the TF antibody RD010 (G) (same section as shown
in E) or with a monoclonal antibody (HAM-56) to human macrophages (H) were compared and indicated that the TF-protein-producing cells
in the necrotic core may be macrophages. Additional adjacent sections in the series were screened with markers specific for smooth muscle
cells (HHF-35), endothelial cells (Ulex europaeus lectin binding), or T cells (anti-Leu4), all of which were negative in this region but labeled
the appropriate cells elsewhere in the section. Arrows point to two cholesterol clefts followed on the serial sections (E-H). (Magnifications are
as follows: for A, x760; for B, x615; for C, G, and H, x310; for D, x1230; for E, x75; for F, x760.)
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Finally, as with the normal vessels, no TF mRNA or protein
was detected in either the endothelium lining the vascular
surface or the small vessels within the plaques.
It was possible to confirm that the protein staining and the
in situ hybridization labeled the same regions on serial
sections (see Fig. 1 E-G). In a few instances we could identify
the same cell on two adjacent serial sections and show that
this cell was positive with both the TF antibody and the in situ
mRNA hybridization. This observation served as a control
for both the immunohistochemistry and hybridization analysis. Additional controls were done on serial sections in
every experiment. The in situ hybridizations were controlled
by hybridization of serial sections with platelet-derived
growth factor A chain or platelet-derived growth factor
receptor-specific riboprobes (17). Different patterns of hybridization were seen with these probes compared to TF. TF
immunohistochemistry was always controlled by incubation
of serial sections with preimmune serum that failed to label
any cells at all.
All of the carotid endarterectomy specimens examined (n
= 16) showed positive TF protein staining in some region of
the plaque. Prominent staining of regions surrounding the
cholesterol clefts in the necrotic core was a feature observed
in five out of seven plaques in which this feature was present.
The others showed variable staining in monocytes, macrophage foam cells, or mesenchymal-appearing intimal cells
(17). A femoral plaque obtained by endarterectomy was
examined and showed TF protein staining consistent with
that seen in the carotid plaques. The mRNA hybridizations
were in agreement with the immunohistochemistry and all six
carotid plaques examined by in situ hybridization had positive intimal cells.
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DISCUSSION
The purpose of these experiments was to localize sites of TF
biosynthesis in both the normal and atherosclerotic vessel. In
the normal vessel, we have shown by immunohistochemistry
and in situ hybridization that TF is synthesized by scattered

cells in the tunica media and fibroblasts in the adventitia
surrounding the vessels. We did not find any evidence of TF
mRNA or protein localization in endothelial cells of any
vessel studied. Previous cell culture work has suggested that
induction of TF synthesis by endothelial cells represents a
major procoagulant mechanism by which endothelial cells
participate in homeostasis (24). However, cultured fibroblasts (24-26) and vascular smooth muscle cells (25) have
been shown to produce TF at much higher levels. It is not
clear if induction of endothelial TF biosynthesis is a normal
in vivo mechanism by which the endothelium modifies
homeostasis or represents the response of the endothelium to
infection and endotoxin stimulation.
Atherosclerotic plaques were examined and found to have
many more TF mRNA-containing cells and stronger TF
protein staining than the media of normal saphenous veins,
internal mammary artery, or regions of normal media underlying the plaque. TF mRNA was found in mesenchymal-like
intimal cells in the atherosclerotic intima as well as in
macrophages and cells adjacent to the cholesterol clefts.
Immunohistochemistry indicated that there was a considerable amount of TF protein trapped in the extracellular matrix
of the necrotic core of the atherosclerotic plaque. This was
not cell-associated but was probably synthesized locally
since cells adjacent to these regions contained TF mRNA.
There is no evidence that TF is a secreted protein (5, 8);
however, it is possible that the TF protein found in the
necrotic core may be shed from the surfaces of the synthesizing cells and trapped in the surrounding matrix. Alternatively, the TF protein in this region may originate from cells
that have died and left TF-rich membranes behind.

Proc. Natl. Acad Sci. USA 86

(1989)

The production of TF by macrophages has been demonstrated by other investigators (27, 28). The immunostaining of
macrophage foam cells suggests that in these cells TF is
intracellular as well as possibly cell surface associated. It is
not clear to what extent such stores of TF are macrophagederived or whether this protein originates from phagocytosis
of surrounding necrotic core debris. It is interesting to note
that Levy et al. (28), have found that certain lipoprotein
fractions can induce procoagulant activity originating from

monocytes/macrophages.
Evidence indicates (29) that TF-initiated coagulation is the
major in vivo coagulant pathway. It is a highly thrombogenic
protein and requires only phospholipid and factor VII/VIa
for its activity. The TF-factor VIIa complex directly activates factor IX and X leading to the generation of thrombin.
Factor VII is normally present in blood but requires binding
to TF for activation offactors IX and X. Since normally there
is no in vivo coagulation in the absence of vascular damage,
it is reasonable to assume that TF is not exposed to blood (7,

29). This is consistent with our findings, since normal vessel
endothelial cells in direct contact with the blood do not
synthesize or store TF. TF is found in scattered smooth
muscle-like cells in the tunica media and adventitial cells
adherent to the vessel. Vessel wall rupture into these areas
would be required to expose the blood to significant stores of
procoagulant TF activity. Zaugg (30) has shown that damaged
human aorta exhibits factor VII-dependent procoagulant
activity, in support of this hypothesis.
Advanced human atherosclerosis is characterized by intimal smooth muscle cell proliferation accompanied by accumulation of fats, inflammatory cells including macrophages,
and T cells within the atherosclerotic plaque (24, 31, 32).
Commonly, the critical event that converts an asymptomatic
atherosclerotic plaque into a symptomatic one is thrombosis
(33-35), whereas nondiseased arteries rarely become thrombotic. It has been suggested that plaque rupture is the integral
event that precipitates clot formation (36-39). An occlusive
mural thrombus accompanies most cases of acute myocardial
infarctions (40-43). Plaque rupture or cracking that exposes
the necrotic core region to the lumen is usually found to
underlie such thrombi in both the coronary (33, 44, 45) and
cerebral arteries (46). The source of the thrombogenicity of
the plaque has not previously been determined, but it has
been suggested that coagulation occurs when blood components come into contact with fats or the collagen matrix
within the plaque. Our studies clearly demonstrate that there
is significant synthesis of TF in atherosclerotic plaques
accompanied by strong staining of TF protein in the necrotic
core and in foam cell-rich regions of the plaque. These results
suggest that overproduction and/or trapping of TF protein in
the atherosclerotic plaque may play a significant role in the
thrombosis associated with plaque rupture.
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